[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2587591T3 - Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino - Google Patents

Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino Download PDF

Info

Publication number
ES2587591T3
ES2587591T3 ES14188791.9T ES14188791T ES2587591T3 ES 2587591 T3 ES2587591 T3 ES 2587591T3 ES 14188791 T ES14188791 T ES 14188791T ES 2587591 T3 ES2587591 T3 ES 2587591T3
Authority
ES
Spain
Prior art keywords
breast cancer
cancer recurrence
patient
endocrine treatment
predicting breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14188791.9T
Other languages
English (en)
Inventor
Christoph Petry
Inke Sabine Feder
Mathias Gehrmann
Guido Henning
Karsten Weber
Christian VON TÖRNE
Ralf Kronenwett
Mareike Dartmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sividon Diagnostics GmbH
Original Assignee
Sividon Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sividon Diagnostics GmbH filed Critical Sividon Diagnostics GmbH
Application granted granted Critical
Publication of ES2587591T3 publication Critical patent/ES2587591T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un método para predecir el resultado del cáncer de mama en un tumor positivo para receptores de estrógeno y negativo para HER2 de un paciente con cáncer de mama, comprendiendo dicho método: (a) determinar en una muestra tumoral de dicho paciente los niveles de expresión de ARN de los siguientes 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, y MGP (b) combinar matemáticamente los valores de los niveles de expresión para los genes de dicho conjunto cuyos valores se determinaron en la muestra tumoral para proporcionar una puntuación combinada, en donde dicha puntuación combinada es indicativa de una prognosis de dicho paciente.
ES14188791.9T 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino Active ES2587591T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158561 2010-03-31
EP10158561 2010-03-31

Publications (1)

Publication Number Publication Date
ES2587591T3 true ES2587591T3 (es) 2016-10-25

Family

ID=43857901

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11710526.2T Active ES2525382T3 (es) 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
ES14188791.9T Active ES2587591T3 (es) 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES11710526.2T Active ES2525382T3 (es) 2010-03-31 2011-03-29 Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino

Country Status (17)

Country Link
US (5) US20130065786A1 (es)
EP (2) EP2553118B1 (es)
JP (2) JP5940517B2 (es)
KR (1) KR101864855B1 (es)
CN (2) CN105821125A (es)
BR (2) BR122020016370B1 (es)
CA (1) CA2793133C (es)
ES (2) ES2525382T3 (es)
HK (1) HK1181817A1 (es)
HU (1) HUE030164T2 (es)
MX (1) MX2012011167A (es)
PL (2) PL2845911T3 (es)
PT (2) PT2553118E (es)
RU (1) RU2654587C2 (es)
UA (1) UA110790C2 (es)
WO (1) WO2011120984A1 (es)
ZA (1) ZA201207229B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
CN105821125A (zh) 2010-03-31 2016-08-03 斯维丹诊断有限责任公司 用于内分泌治疗下的乳腺癌复发预测的方法
ES2608322T3 (es) 2011-07-28 2017-04-07 Sividon Diagnostics Gmbh Procedimiento para predecir la respuesta a la quimioterapia en un paciente que padece o está en riesgo de desarrollar cáncer de mama recurrente
US20140296085A1 (en) * 2011-11-08 2014-10-02 Genomic Health, Inc. Method of predicting breast cancer prognosis
MX369628B (es) * 2012-05-22 2019-11-14 Nanostring Technologies Inc Genes nano46 y metodos para predecir el resultado del cancer de mama.
WO2013188600A1 (en) * 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
DK2951317T3 (en) 2013-02-01 2018-01-15 Sividon Diagnostics Gmbh PROCEDURE FOR PREDICTING THE BENEFIT OF INCLUSING TAXAN IN A CHEMOTHERAPY PLAN FOR BREAST CANCER PATIENTS
KR20160005731A (ko) * 2013-05-07 2016-01-15 국립연구개발법인 고쿠리츠간켄큐센터 위암의 재발을 예측하는 방법
AU2014265623A1 (en) * 2013-05-13 2015-11-26 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
WO2015015000A1 (en) * 2013-08-02 2015-02-05 Université Catholique de Louvain Signature of cycling hypoxia and use thereof for the prognosis of cancer
BR112016005225B1 (pt) * 2013-09-11 2023-11-14 Bio Theranostics, Inc Métodos para avaliar câncer de mama em um indivíduo
CN105793437B (zh) * 2013-09-23 2020-12-15 芝加哥大学 关于dna损伤制剂用于癌症治疗的方法和组合物
KR101548830B1 (ko) * 2013-12-30 2015-08-31 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물
EP3097421B1 (en) * 2014-01-22 2019-11-13 Koninklijke Philips N.V. Improved stratification of patients for assessing the suitability of a therapy
RU2566732C1 (ru) * 2014-07-08 2015-10-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования лимфогенного метастазирования при инвазивной карциноме неспецифического типа молочной железы
CN104263815B (zh) * 2014-08-25 2017-01-25 复旦大学附属肿瘤医院 一组用于激素受体阳性乳腺癌预后的基因及其应用
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CA2980562A1 (en) 2015-03-25 2016-09-29 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
WO2017153546A1 (en) 2016-03-09 2017-09-14 Sividon Diagnosticg Gmbh Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy
CN115873110A (zh) * 2016-04-14 2023-03-31 刘扶东 抑制scube2，一种新颖vegfr2辅助受体，抑制肿瘤血管发生
PL3449017T3 (pl) * 2016-04-29 2022-06-27 Board Of Regents, The University Of Texas System Ukierunkowane pomiary aktywności transkrypcyjnej związanej z receptorami hormonów
CN106480201A (zh) * 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒
EP3985127A1 (en) * 2016-10-27 2022-04-20 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
KR101896545B1 (ko) * 2016-11-25 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
RU2671557C1 (ru) * 2017-07-10 2018-11-02 Александр Григорьевич Тоневицкий Набор реагентов для определения риска возникновения рецидива онкологических заболеваний молочной железы
CA3075265A1 (en) * 2017-09-08 2019-03-14 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
CN108715804A (zh) * 2018-05-14 2018-10-30 浙江大学 一种群智能寻优的肺癌癌细胞检测仪
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
US20220042999A1 (en) * 2018-12-06 2022-02-10 Georgia State University Research Foundation, Inc. Quantitative Centrosomal Amplification Score to Predict Local Recurrence of Ductal Carcinoma In Situ
EP3994282A1 (en) * 2019-07-05 2022-05-11 Intellexon GmbH Determining individual hla patterns, use as prognosticators, target genes and therapeutic agents
JP2022547735A (ja) * 2019-09-16 2022-11-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 乳房がんの分子特徴付けに基づく処置の方法
KR102325945B1 (ko) * 2020-04-22 2021-11-12 아주대학교산학협력단 두경부암 예후 예측용 바이오마커 조성물
CN112852968A (zh) * 2021-04-08 2021-05-28 杨文琳 基于免疫相关lncRNA构建三阴性乳腺癌风险预测方法
CN114480652A (zh) * 2022-02-21 2022-05-13 深圳市陆为生物技术有限公司 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
JP4277452B2 (ja) 2000-02-25 2009-06-10 ソニー株式会社 記録装置、再生装置
EA006512B1 (ru) * 2001-04-27 2005-12-29 Институт молекулярной биологии им. В.А.Энгельгардта РАН Способы анализа последовательностей нуклеиновых кислот с использованием биологического олигонуклеотидного микрочипа и наборы для их осуществления
US7297480B2 (en) 2001-06-28 2007-11-20 Dermtech International Method for detection of melanoma
US20040002067A1 (en) 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
WO2005083429A2 (en) * 2004-02-20 2005-09-09 Veridex, Llc Breast cancer prognostics
KR20070068401A (ko) * 2004-09-22 2007-06-29 트리패스 이미징, 인코포레이티드 암의 예후에 대한 마커 후보의 분석 및 최적화를 위한 방법및 컴퓨터 프로그램 제품
EP1815014B1 (en) 2004-11-05 2012-03-21 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2596640A1 (en) 2005-02-04 2006-08-10 Rosetta Inpharmatics Llc Methods of predicting chemotherapy responsiveness in breast cancer patients
EP1880335A1 (en) * 2005-05-13 2008-01-23 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0512299D0 (en) 2005-06-16 2005-07-27 Bayer Healthcare Ag Diagnosis prognosis and prediction of recurrence of breast cancer
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
WO2008006517A2 (en) * 2006-07-13 2008-01-17 Siemens Healthcare Diagnostics Gmbh Prediction of breast cancer response to taxane-based chemotherapy
EP2061885A4 (en) * 2006-09-15 2011-03-09 Univ Mcgill BREAST CANCER INDICATOR DERIVED FROM STROMA
JP2010511630A (ja) 2006-12-01 2010-04-15 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 自己組織化ブロックコポリマーのベシクル、ならびにその生成および使用法
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009095319A1 (en) 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
SI2297359T1 (sl) * 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
US20110166838A1 (en) * 2008-06-16 2011-07-07 Sividon Diagnostics Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
EP2304630A1 (en) 2008-06-16 2011-04-06 Sividon Diagnostics GmbH Molecular markers for cancer prognosis
EP2163649A1 (en) * 2008-09-11 2010-03-17 Fédération Nationale des Centres de Lutte Contre le Cancer Molecular classifier for evaluating the risk of metastasic relapse in breast cancer
KR101161789B1 (ko) 2008-12-10 2012-07-03 한국생명공학연구원 간암에 대한 신규 바이오마커 및 그의 용도
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
US20120065084A1 (en) 2009-04-17 2012-03-15 Universite Libre De Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
US8546091B2 (en) 2009-05-22 2013-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services AKT phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
WO2011121028A1 (en) 2010-03-30 2011-10-06 Siemens Healthcare Diagnostics Inc. Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer
CN105821125A (zh) 2010-03-31 2016-08-03 斯维丹诊断有限责任公司 用于内分泌治疗下的乳腺癌复发预测的方法
CA2835179A1 (en) 2011-05-06 2012-11-15 Xentech Markers for cancer prognosis and therapy and methods of use
ES2608322T3 (es) 2011-07-28 2017-04-07 Sividon Diagnostics Gmbh Procedimiento para predecir la respuesta a la quimioterapia en un paciente que padece o está en riesgo de desarrollar cáncer de mama recurrente
EP2786140A4 (en) 2011-11-28 2015-10-28 Nat Res Council Canada PACLITAXEL REACTION MARKERS FOR CANCER
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
EP3105344A1 (en) 2014-02-12 2016-12-21 Myriad Genetics, Inc. Method for predicting the response and survival from chemotherapy in patients with breast cancer
CN106480201A (zh) 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒

Also Published As

Publication number Publication date
WO2011120984A1 (en) 2011-10-06
US20210123107A1 (en) 2021-04-29
KR20130010048A (ko) 2013-01-24
JP2016189781A (ja) 2016-11-10
US10577661B2 (en) 2020-03-03
AU2011234573B2 (en) 2015-10-01
CN102971435A (zh) 2013-03-13
BR122020016370B1 (pt) 2021-05-11
ES2525382T3 (es) 2014-12-23
US20200224281A1 (en) 2020-07-16
RU2012146343A (ru) 2014-05-10
US20240229150A1 (en) 2024-07-11
US10851427B2 (en) 2020-12-01
JP5940517B2 (ja) 2016-06-29
BR112012024718A2 (pt) 2017-01-10
HUE030164T2 (en) 2017-05-29
EP2845911A1 (en) 2015-03-11
PT2845911T (pt) 2016-08-25
US20170067118A1 (en) 2017-03-09
EP2845911B1 (en) 2016-05-18
HK1181817A1 (en) 2013-11-15
PL2553118T3 (pl) 2015-03-31
MX2012011167A (es) 2013-02-07
KR101864855B1 (ko) 2018-07-13
RU2654587C2 (ru) 2018-05-21
ZA201207229B (en) 2013-06-26
CA2793133C (en) 2019-08-20
US11913078B2 (en) 2024-02-27
PT2553118E (pt) 2014-12-17
UA110790C2 (uk) 2016-02-25
CA2793133A1 (en) 2011-10-06
CN105821125A (zh) 2016-08-03
PL2845911T3 (pl) 2017-01-31
EP2553118A1 (en) 2013-02-06
CN102971435B (zh) 2016-05-11
EP2553118B1 (en) 2014-10-15
AU2011234573A1 (en) 2012-09-20
US20130065786A1 (en) 2013-03-14
JP2013523105A (ja) 2013-06-17

Similar Documents

Publication Publication Date Title
ES2587591T3 (es) Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino
Ratner et al. MicroRNA signatures differentiate uterine cancer tumor subtypes
Butz et al. Exosomal microRNAs are diagnostic biomarkers and can mediate cell–cell communication in renal cell carcinoma
Xie et al. Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis
Li et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Li et al. MiR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
SG10201908277TA (en) Method of determining the risk of developing breast cancer by detecting the expression levels of micrornas (mirnas)
NZ722902A (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
Yu et al. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
JP2014532428A5 (es)
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
Jing et al. Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
WO2012079059A3 (en) Post-treatment breast cancer prognosis
Farhangian et al. Differential expression of long non-coding RNA SOX2OT in gastric adenocarcinoma
Moratin et al. MicroRNA expression correlates with disease recurrence and overall survival in oral squamous cell carcinoma
Zhuang et al. Downregulation of miR-361-5p associates with aggressive clinicopathological features and unfavorable prognosis in non-small cell lung cancer
Mao et al. MicroRNA‐222 expression and its prognostic potential in non‐small cell lung cancer
Abak et al. Analysis of miRNA-221 expression level in tumors and marginal biopsies from patients with breast cancer (cross-sectional observational study)
WO2012166700A3 (en) Molecular profiling of a lethal tumor microenvironment
Zhang et al. Clinicopathological and prognostic significance of miR-4317 expression in gastric cancer patients.
Ju et al. Identification of colorectal cancer recurrence-related microRNAs